bepirovirsen

LONDON, United Kingdom, April 28, 2026 GSK has announced that its investigational antisense oligonucleotide therapy bepirovirsen has been accepted...

London, UK | March 27, 2026 EMA Accepts First-in-Class Hepatitis B Therapy for Review GSK has announced that the...